References
- Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007;119:881-91
- Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003;111:437-48
- WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53 (Suppl 54):4-30
- Fiocchi A, Pajno GB, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged less than 6 years. Ann Allergy Asthma Immunol 2005;95:254-8
- Di Rienzo V, Minelli M, Musarra A, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005;35:560-4
- Rossi RE, Monasterolo G. A pilot study of feasibility of ultra-rush (20-25 min) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 2005;18:277-85
- Gammeri E, Arena A, D’Anneo R, et al. Safety and tolerability of ultra-rush (20 min) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol Immunopathol 2005;33:221-3
- Tripodi S, Di Rienzo Businco A, Benincori N, et al. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol 2006;139:149-52
- Vervloet D, Birnbaum J, Laurent P, et al. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. Int Arch Allergy Immunol 2007;142:239-46
- Wilson DR, Torres-Lima M, Durham S. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:4-12
- Smith M, Emberlin J. Constructing a 7-day ahead forecast model for grass pollen at north London, United Kingdom. Clin Exp Allergy 2005;35:1400-6
- Andrè C, Fadel R. Anaphylaxis caused by sublingual immunotherapy? Allergy 2007;62:1220-1
- Bernardini R., Campodonico P, Burastero S, et al. Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study. Curr Med Res Opin 2006;22:1515-22
- Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass pollen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40
- Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45
- Penagos M, Passalacqua G, Compalati E, et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133:599-609
- Bousquet J. Sublingual immunotherapy: from proven prevention to putative rapid relief of allergic symptoms. Allergy 2005;60:1-3